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ABSTRACT 
 
The high morbidity and mortality of canine osteosarcoma (OS) despite standard therapy 
warrants the need to investigate new treatment options.  One avenue in exploring novel therapies 
is drug repurposing – using drugs with known dosing, toxicity profiles, and pharmacokinetics, 
and re-purposing them “off-label” for their pharmacologic effects for other diseases.  In the 
search for novel therapies for canine osteosarcoma (OS), the benzimidazole (BZ) drugs, a class 
of safe and inexpensive anti-parasitics, were identified as potential novel therapeutics.   
Benzimidazole (BZ) drugs are used routinely as effective anti-parasitics
 
in both human 
and veterinary medicine.  Their safety is well-established and side effects are minimal in most 
veterinary species including dogs.  Safety has been described both with short-term high doses as 
well as long-term chronic dosing in dogs and other species with minimal adverse effects.    
BZs have demonstrated in vitro and in vivo anti-cancer effects in both people and animal 
tumor models.  The mechanism of BZs is thought to be similar to the microtubule inhibitory 
actions of traditional chemotherapeutic drug classes such as taxanes and vinca alkaloids, leading 
to metaphase arrest (G2/M phase) and tumor cell apoptosis.
 
 BZs also demonstrate indirect anti-
cancer activity by vascular disruption of endothelial cells and reduction in cancer cell secretion 
of the angiogenic cytokine vascular endothelial growth factor (VEGF).  
In human OS, mitotic spindle inhibitors are routinely used as an adjuvant chemotherapy 
agent, and similarly mitotic spindle inhibitors demonstrate effect for canine OS.  Given the 
proposed activity at the mitotic apparatus, BZs may have similar activity in canine osteosarcoma.  
In addition to direct cytotoxic effects, BZs may possess indirect anti-angiogenic effects in canine 
OS, including modulation of VEGF.  In human OS, increased VEGF expression is a negative 
prognostic factor
 
and a strong predictor of metastasis and poor survival. Similarly serum VEGF 
is elevated in many canine cancers including OS and correlates with poor disease free interval.  
This supports a role for VEGF-induced angiogenesis in the development and progression of 
metastatic disease in dogs with OS and provides another potential anti-neoplastic mechanism for 
BZs.   
We hypothesize that BZs have direct and indirect anti-neoplastic effects in vitro for 
canine OS.  The aims of this study were to assess the in vitro effects of the clinically-used 
veterinary benzimidazoles [mebendazole (MBZ), fenbendazole (FBZ), and albendazole (ABZ)] 
iii 
 
on a canine OS cell line.  Cell lines were evaluated for dose-dependent anti-neoplastic effects on 
the functions of cell proliferation, cell-cycle phase distribution, and cell death. Soluble VEGF 
secretion and the effect on tubulin polymerization were also evaluated in vitro.   Specifically, the 
in vitro effects of ABZ, FBZ and MBZ on D17 canine OS cells were investigated by 
characterizing 1) cell proliferation with an MTS assay, 2) apoptosis via flow cytometry, 3) 
VEGF secretion via ELISA and 4) tubulin polymerization and 5) cell cycle distribution via flow 
cytometry.  
The results of this study demonstrate that treatment with BZs inhibits cell proliferation in 
a dose and time dependent fashion.  Flow cytometry demonstrates that BZ treatment induces 
cells arrest in G2/M and subsequently apoptosis.  Mechanistically, the BZs affect microtubules 
by inhibition of polymerization.  Additionally, exposure to the BZs results in decreased secretion 
of VEGF from D17 OS cells.   
 Our findings demonstrate that the clinically used veterinary BZs (ABZ, FBZ, and MBZ) 
possess anti-neoplastic activity in an OS cell line.  In addition to direct effects on tubulin 
polymerization, cell cycle, proliferation, and cytotoxicity, BZs demonstrate indirect activity 
through modulation of a key pro-angiogenic cytokine.  These findings are similar to what we 
would expect with a traditional mitotic spindle inhibitor such as a vinca alkaloid.  In vitro effects 
are apparent at drug doses achievable in vivo with minimal expected adverse effects.   This data 
supports the continued investigation into the use of BZs as an adjunctive therapy for canine 
osteosarcoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGMENTS 
 
I would like to thank the members of my graduate committee: Drs. Anne Barger, Tim 
Fan and Jackie Wypij.   I would also like to thank Holly Pondenis, you are amazing and we don’t 
tell you enough. 
This manuscript is dedicated to all the people in my life, who have stood by me through it 
all, lived with integrity over impropriety and because of their strength have made this world a 
better place.  You know who you are and I love you for it.  
 
 
Be who you are and say what you feel because those who mind don’t matter and those 
who matter don’t mind. 
         -Dr. Seuss 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
 
CHAPTER 1: INTRODUCTION ........................................................................................1 
CHAPTER 2: LITERATURE REVIEW .............................................................................3 
CHAPTER 3: IN VITRO EFFECTS OF BENZIMIDAZOLES ON THE CANINE 
OSTEOSARCOMA CELL LINE D17 ..............................................................................19 
CHAPTER 4: IN VITRO EFFECTS OF BENZIMIDAZOLES ON VEGF 
SECRETION IN D17 CELLS ...........................................................................................27 
CHAPTER 5: DISCUSSION AND CONCLUSIONS…………………………………..31 
CHAPTER 6: FIGURES AND TABLES.……………………………………………….35 
REFERENCES…………………………………………………………………………...50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
 
Osteosarcoma (OS) is the most common skeletal tumor in dogs and is associated with 
high morbidity (severe bone pain) and mortality.  The addition of adjunctive chemotherapy to 
local surgery (amputation or limb-spare) has led to prolonged survival time yet this tumor is 
highly metastatic and is considered terminal in most patients at diagnosis.  Doxorubicin and/or 
platinum agents are considered standard of care adjuvant chemotherapeutics; however other drug 
classes such as microtubule inhibitors (vinca alkaloids and taxanes) have shown promise in both 
canine
1-3
 and human OS.
4-6
  The in vivo effects of systemic chemotherapy are thought to induce 
cytotoxicity of OS cells that have spread microscopically to the lungs.  At both the primary 
(bone) and metastatic (lung) sites, tumors must promote malignant angiogenesis, or new blood 
vessel formation, to provide nutrients and oxygen for sustained growth and survival.  Vascular 
endothelial growth factor (VEGF) is a key cytokine regulating malignant angiogenesis and its 
expression in human OS is a negative prognostic factor
7
and strong predictor of metastasis and 
poor survival.
8
 Similarly, serum VEGF is elevated in many canine cancers including OS
9
and 
correlates with poor disease free interval,
10
 demonstrating the role of VEGF-induced 
angiogenesis in the progression of metastatic disease in dogs with OS.  Despite advances in 
veterinary oncology, the standard of care treatment and survival time for dogs with OS has 
remained fundamentally unchanged for twenty years, emphasizing the need for novel therapies. 
One avenue in exploring novel therapies is drug repurposing – using drugs with known dosing, 
toxicity profiles, and pharmacokinetics, and re-purposing them “off-label” for their 
pharmacologic effects for other diseases.   
Benzimidazole (BZ) drugs have been used for decades in human and veterinary medicine 
primarily as effective anti-parasitics.
11, 12
 Benzimidazoles have well-established safety and 
induce minimal adverse side effects in many veterinary species including dogs.  Although 
usually prescribed for short-term usage for parasitic diseases, long-term safety has been reported 
in dogs at doses from 4mg/kg/day for 180 days to 250 mg/kg/day for 30 days for various BZs 
with no adverse effects.   Recently, BZs have demonstrated additional pharmacologic effects, 
including in vitro and in vivo anti-cancer activity in both people and animal tumor models.
13-
15
The mechanism of BZs is thought to be similar to the microtubule (MT) inhibitory actions of 
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clinically used anti-cancer drugs such as taxanes and vinca alkaloids.
16
 These drugs inhibit 
cancer via interaction with tubulin and disruption of MT function, particularly of MTs 
comprising the mitotic spindle apparatus, leading to metaphase arrest (G2/M phase) and tumor 
cell apoptosis. 
4-6, 17
  BZs exhibit direct effects (inhibition of cell proliferation, promotion of 
cytotoxicity) 
13-15
  but also demonstrate indirect anti-cancer activity via modulation of 
angiogenesis, including vascular disrupting effects on endothelial cells and reduction in cancer 
cell secretion of the angiogenic cytokine VEGF.
18-21
 Therefore, BZ anti-cancer activity can be 
attributed to MT inhibition resulting in cancer cell death as well as modulation of VEGF-related 
tumor angiogenesis.
15, 18, 19, 21, 22
    
Based on clinical usefulness in dogs as well as reported anti-cancer activity in other 
species, the BZs fenbendazole (FBZ), mebendazole (MBZ), and albendazole (ABZ) appear the 
most promising of the BZ drug class for further study in pet dogs with cancer.  Canine OS is an 
attractive in vitro tumor model based on reported sensitivity to MT inhibitors 
1-3
and the in vivo 
role of VEGF in angiogenesis and tumor progression. 
9, 10
 We hypothesize that in canine OS cell 
lines, BZs inhibit MT formation resulting in cell-cycle arrest and apoptosis and may induce anti-
angiogenic effects by reducing secretion of vascular endothelial growth factor (VEGF).   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
Osteosarcoma (OS) is the most common skeletal tumor in dogs as well as in children.
23
 
Osteosarcoma causes malignant osteolysis resulting in severe pain.  Affected dogs are presented 
by their owners for acute or chronic lameness with inadequate response to oral analgesics.  In 
human and veterinary medicine, OS is both locally aggressive and highly metastatic, resulting in 
high morbidity and mortality. Treatment with surgical removal (amputation or limb-spare 
surgery) in conjunction with chemotherapy (carboplatin, cisplatin, or doxorubicin) provide the 
longest median survival times in dogs.
24
  Despite aggressive therapy, most dogs will die of 
metastatic disease approximately 1 year after diagnosis.
25-27
  In people, the overall prognosis for 
localized disease is 65% survival at 5 years.
28
  Given this poor survival, current treatment is 
aimed at alleviation of pain and reduction of tumor progression.  The pain associated with OS is 
a result of malignant osteolysis and bone remodeling incited by the increased neoplastic 
osteoblastic as well as imbalanced osteoclastic activity. Osteolysis is also necessary in the 
establishment of bone metastasis.
29
 
Investigation of novel therapies for the adjuvant treatment of OS is important to improve 
the survival and quality of life for these patients.  Chemotherapy drugs with alternative 
mechanisms of action may help slow local tumor progression as well as delay micrometastatic 
disease which is thus far nearly inevitable in canine OS. Osteosarcoma cell lines and naturally 
occurring tumors have shown sensitivity to non-standard chemotherapy drugs including the 
mitotic spindle inhibitors vinca alkaloids and taxanes.
1, 4, 6, 30
 However, these chemotherapy 
drugs retain similar adverse side effect profiles to clinically used drugs effective for OS and thus 
are unlikely to be superior in clinical use.  Novel mitotic spindle inhibitors such as BZs that have 
limited toxicity profiles yet possess anti-cancer activity could be a viable addition to the current 
standard of care protocols.  
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2.2 BENZIMIDAZOLES  
2.2.1 Use in Veterinary Medicine  
A benzimidazole (BZ) is a heterocyclic aromatic organic compound that is formed by the 
fusion of an imidazole and benzene.
31
 Structurally, the benzene is fused to the 4 and 5 position of 
the heterocyclic imidazole. (Figure 1) Chemical modifications in the 2 and 5 positions can also 
increase the activity of the drugs.
32
 In 1961, 2-(4’-thiazolyl) benzimidazole or thiabendazole was 
found to have broad spectrum activity against gastrointestinal parasites.  Following this 
discovery, additional compounds; parabendazole, cambendazole, mebendazole, and 
oxidbendazole were manufactured and intensely evaluated for anthelmintic use.
33
  Today, BZs 
are used against helminiths, fungi and peptic ulcers in people.
34
 The BZ family of drugs is most 
frequently used in veterinary medicine for the treatment of nematode and trematode infections.  
They are poorly water soluble leading to limited absorption.  The formulation of pro-drugs has 
helped to increase absorption however the BZs are most often given as an oral powder or paste 
for gastrointestinal parasites and as such intestinal absorption is not important for their primary 
use.  BZs are routinely prescribed for many veterinary species including dogs. 
 
2.2.2 Mechanism of action, toxicity, metabolism and efficacy 
As an antiparasitic, a BZ acts by binding to the tubulin within the parasite resulting in 
inhibition of cell division and polymerization of microtubules via disruption of the mitotic 
spindle. In vitro, BZs prevent polymerization of tubulin into microtubules via suppression of the 
mitotic spindle and disruption of the microtubule-kinetochore interaction.  The loss of tension 
leads to poor chromosomal alignment.
35
  This causes the cells to arrest in G2/M and the cell 
cannot enter mitosis.  Cell death ensues via apoptosis.  BZs can also uncouple oxidative 
phosphorylation in mitochondria.  This disruption causes altered metabolism and inhibition of 
cellular transport in the cell.
33,36
 In a time dependent manner, energy reserves become depleted 
and waste excretion becomes inhibited leading to cell death.
37
 Possible additional mechanisms of 
action have been reported with other BZs.  The BZ carbendazim appears to directly target DNA; 
it can induce oxidative stress and epigenetic regulation through hypomethylation. Global changes 
in methylation patterns are a characteristic trait of many tumors. Benzimidazole derivatives have 
also been used as anti-cancer inhibitors of PgP (a drug efflux pump important in chemo-
resistance) and topoisomerase I (an enzyme that that relaxes DNA supercoiling during 
5 
 
replication and transcription).
38
  It has also been proposed that BZs can inhibit histone 
deacetylase resulting in hyperacetylation of histones and subsequently affect gene 
expression.
34
Mebendazole (MBZ) has been shown to induce apoptosis through inactivation of 
Bcl-2, a protein which suppresses apoptosis by preventing the activation of the caspase pathway.  
In addition, some BZ derivatives have demonstrated inhibition of EGFR, VEGFR-2 and PDGFR 
kinase activity, which are commonly upregulated in many cancers.
38, 39
 Thus, although 
microtubule inhibition resulting in cell cycle arrest and apoptosis is likely to be the main anti-
cancer mechanism of BZs, other intracellular mechanisms may play a role. 
 
2.2.3 Safety, toxicity and metabolism 
Hundreds of BZ derivative drugs exist, though few of the compounds have 
40
been 
thoroughly evaluated. The overall safety of the BZs has been well documented in human and 
veterinary medicine.  In general this class of drugs is well tolerated and has minimal toxicity.   
The largest volume of information is available for albendazole (ABZ). Bone marrow toxicity 
resulting in leukopenia and anemia has been reported in dogs, cats and people.
41
 Reversible bone 
marrow hypoplasia secondary to ABZ administration has been noted in a dog, though this has 
never been reported in people. Bone marrow toxicity is less frequent with fenbendazole (FBZ) 
administration, possibly due to decreased gastrointestinal absorption compared to ABZ. 
36
ABZ 
undergoes 1
st
 pass metabolism in the liver (people, dogs and rats) into its active form albendazole 
sulphoxide which is 70% protein bound.  Clearance of the parent drug is rapid.
41, 42
 No 
comprehensive pharmacokinetic study has been conducted. Fatty meals enhance oral absorption 
up to 5 times in people and animals. Multiple studies examining doses in rats ranging from 0-
168mg/kg daily (for 1-6 months) showed good tolerance at doses less than 30mg/kg. At doses 
higher than 30mg/kg/day for 6 months, reported toxicities included anemia, leukopenia, 
decreased body weight, relative liver enlargement and hypocellular bone marrow.
41
These 
findings are similar between dogs and rats. ABZ has been associated with teratogenic and 
embryogenic effects in rats. At doses of 50mg/kg twice daily anorexia has been noted.  The oral 
LD50 of ABZ is >1320 mg/kg (rat) and >3000 mg/kg (mouse). No maximum toxic dose has 
been established in the dog.
43,44
 
Fenbendazole is more than 50% metabolized in the liver in rats; no canine metabolic data 
is available. It has a greater affinity for helminth tubulin than mammalian tubulin.
13
 The major 
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metabolites of FBZ are oxfendazole, sulfoxide and sulfone.
45
 Absorption is quite variable and 
contradictory reports exist regarding the addition of a fatty meal to increase gastrointestinal 
absorption.
12
 In toxicity studies, no adverse effects were noted at FBZ doses of 250mg/kg/day for 
30 days or 125mg/kg for 90 days.
36
 The oral LD50 of FBZ is >500mg/kg in rats.
46
 
Mebendazole has limited solubility in water affecting its behavior and absorption in the 
body though uptake is increased with fatty meal.  It undergoes 1
st
 pass metabolism in the 
intestinal wall and liver in people and animals and primarily excreted in the bile and urine. The 
metabolites have not been individually identified, and are reported to lack anti-parasitic 
activity.
12, 41
Acute oral toxicity has been investigated in twelve animal species and mebendazole 
was well tolerated by all species. Noted side effects were diarrhea and weight loss in pigs and 
horses. The acute oral LD50 >640 mg/kg in dogs.   Chronic oral toxicity has been investigated in 
four animal species including dogs.  Oral administration of mebendazole to dogs at doses up to 
40 mg/kg once daily for two years did not cause any significant abnormality.
47, 48
 Overall, the BZ 
drugs have minimal toxicity and are well tolerated with variable absorption. (Table 1) 
 
2.2.4 Benzimidazoles as anti-cancer agents 
In the early 1950s the anti-cancer potential of the BZs were first discovered when they 
were added to other compounds such as nitrogen mustard and showed inhibition of carcinoma, 
mammary adenocarcinoma and sarcoma in mice.
49
  In the 1980s further work with various 
benzimidazole alkylating agents in combination with nitrogen mustard derivatives and 
benzothiazole alkylating agents showed efficacy against lymphocytic leukemias.
50, 51
Over the 
next 30 years BZs were more thoroughly evaluated for their anticancer effects. Multiple BZ 
analogs have been evaluated in people and rodent tumor models.  The results are extremely 
variable, dependent not only on species and tumor type but also dose rate and time.  Early work 
with seven BZ analogs revealed significant inhibition of growth to normal lymphocytes via 
mitotic arrest by MBZ, parabendazole, cambendazole and FBZ.  Other analogs, thiabendazole 
and oxfendazole (OFZ) showed no activity.
52
   Limited information regarding the use of FBZ in 
both people and animals as a specific anticancer therapy exists.  It was noted incidentally that 
FBZ routinely administered in rat food inhibited tumor growth of human xenograft lymphoma 
when combined with dietary vitamin supplementation (vitamin B, D, K, E, and A).
13
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2.2.5 In vitro and in vivo evidence of anti-cancer effects 
Many BZ derivatives have been evaluated in vitro and in vivo over the last 20 years. ABZ 
has previously been shown to have strong antiproliferative in vivo and in vitro effects against 
colorectal cancer and hepatocellular carcinoma (HT-29) in people.
14, 53-55
 MBZ induces mitotic 
arrest in non-small cell lung cancer in mice xenografts.
56
 In another study, MBZ had antitumor 
effects on human lung cancer cell lines in vitro and in vivo. Flubendazole has demonstrated 
clinical activity against leukemia and myeloma xenografts especially in combination with vinca 
alkaloids.
57
 A larger study demonstrated cytotoxic effects of carbendazim and benomyl on 
immortalized human cell lines and primary cell cultures from cancer patients, including 
leukemia, myeloma, lymphoma, small cell lung cancer, renal and cervical adenocarcinoma.
34
 
Benomyl appears more potent than the metabolite carbendazim (noted with many drugs) and is 
more effective against hematologic malignancies while the metabolite carbendazim is more 
effective against solid tumors. 
34
  Carbendazim also demonstrated potent antitumor activity 
against murine B16 melanoma and human HT-29 colon carcinoma cell lines.
58
 
More recently, a new generation of synthesized BZ-based agents has also shown 
anticancer effects against murine melanoma models via PARP-1, which has a role in repair of 
single-stranded DNA (ssDNA) breaks.
59
 The addition of BZ ligands to existing drugs such as 
cisplatin analogs has in vitro anti-proliferative effects on human MC7-breast and HeLa cervical 
cancer cell lines.
60
 Derived compounds, such as 2-substituted BZs also have anticancer effects.  
Examples of this include bis-bezimidazole derivatives that interfere with DNA topoisomerase 1 
and are cytotoxic against breast adenocarcinoma and skin epidermoid carcinoma. Another 
example is methyl-2-benzimidazole carbamate; this agent induces apoptosis in cancer cells.
55
  A 
novel derivative, MPTB, can also induce apoptosis in human chondrosarcoma cells.
61
 Various 
derivatives of 2-mercaptobenzimidazoles in one study showed antiproliferative activity with 
notable activity in G2/M phase arrest with time-dependent induction of apoptosis. 
Thiazolobenzoimidazole derivatives also activate apoptosis. 
62
  Thus, many BZ drugs exhibit 
anti-cancer properties, with demonstrated efficacy against a broad spectrum of tumor types and 
several potential mechanisms of action. 
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2.2.6 Benzimidazoles as possible therapy for resistant tumors 
Acquired tumor resistance to chemotherapy necessitates novel therapies for successful 
cancer treatment.  The drugs most often associated with acquired resistance are paclitaxel, 
docetaxel, vinca alkaloids, doxorubicin, daunorubicin, epirubicin, etoposide, dactinomycin, and 
mitomycin C.
63
 Many mechanisms of tumor resistance exist.  A frequently encountered 
mechanism involves cells with the MDR phenotype that utilize alterations in the Golgi apparatus, 
lysosomes and other organelles that affect post-translation pathways.  The Golgi apparatus is 
central to maintaining growth and survival of cancer cells and may be an additional therapeutic 
target site.    A BZ based chemical compound, 2-(substituted phenyl)-benzimidazole or 2 PB can 
displace the resident Golgi proteins by inhibiting its ability to recycle these proteins leading to 
inhibition of cell proliferation. 
64
 Another resistance mechanism involves PARP-1 (Poly (ADP-
ribose) polymerase-1). PARP-1 is activated by DNA damage, causing it to cleave NAD+ and 
transfer ADP-ribose units which aid DNA repair, allowing cancer cells to evade apoptosis 
following DNA damage.  Some cancer cells overexpress PARP-1, making it an attractive target. 
Various formulation and chemical alterations of BZ cores such the addition of a piperidyl or 
pyrrolidinyl +/- an alkyl group on the nitrogen at the 2 position demonstrate positive enzymatic 
and cellular assay results for PARP-1 inhibition.   Continued modifications demonstrate 
improved pharmacokinetic properties and potent oral efficacy, making BZs yet more attractive as 
novel anticancer agents.
59
 
 
2.3 TUBULIN AND MICROTUBULES 
2.3.1 Structure and function 
Tubulin is a heterodimer, made up of andsubunits. The andtubulin subunits 
have masses of 55 kDa and both have approximately 450 amino acid residues.
65, 66They are 
highly conserved across species (60%) and vertebrates have at least 6 genes responsible for 
tubulin formation. Tubulin is subject to multiple post translational modifications which are 
evolutionarily conserved.   These include: acetylation of a lysine near the NH2-terminus of a 
tubulin by acetyltransferase, detyronization which removes the C terminal tyrosine residue of the 
 tubulin, and polyglutamylation, a modification that adds a glutamate side chain to the C 
terminal tail of both andtubulin.66 The tubulin subunits interact in a covalent manner, 
forming a stable cylindrical structure that is 24nm in diameter. The tubulin dimers polymerize to 
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form a protofilament.  This 3-D structure of the microtubule (MT) is composed of 13 
protofilaments.
67
 (Figure 2) Microtubules are an important component of the cytoskeleton and 
play a critical role in many processes such as motility, organelle function and distribution during 
interphase, vesicle trafficking, morphogenesis and chromosome segregation during mitotic cell 
division.  As important parts of the cell scaffold, they help to localize and regulate cell signaling 
proteins.
17, 65
  Many compounds isolated from plants influence MT assembly and stability. These 
include vincas, colchicine, taxol, and epothilone.
66
 The two key binding sites for anti-neoplastic 
drugs are the colchicine and vinblastine binding sites. The colchicine binding site is located at 
the interface between andsubunits of the same heterodimer. Some BZs including MBZ and 
FBZ are reported to bind to the colchicine binding site of mammalian tubulin. The vinblastine 
binding site lies between two tubulin heterodimers and includes tubulin residues that are located 
on the inner lumen of the MT. 
68
 (Figure 3) The combination of the crucial function in cell 
division plus multiple potential drug binding sites make MTs an attractive drug target with 
microtubule inhibitors (MTIs).
69-72
 
 
2.3.2 Tubulin 
There are eight mammalian tubulin and seven mammalian tubulin isotypes. The 
tubulin isotypes (I, II, III, IVa, IVb, V and VI) are highly conserved and are distinguished by 
their C-terminal sequence. 
73
 Aberrant expression of tubulin has been reported in multiple 
cancers and this phenotype may be more aggressive and exhibit drug resistance.  tubulin is 
overexpressed in lung, prostate, ovarian and breast cancer cell lines and is associated with taxol 
drug resistance.
74-76
 Increased expression of V tubulin and taxol resistance has also been 
demonstrated in OS cell lines.
77
  Altered expression of -tubulin isotypes in a taxol-resistant 
canine tumor-derived osteosarcoma-like cell line is reported. 
78
As is typical in cancer therapy, 
there is variability in isotype expression based on tissue type and tumor type in people.  
Investigations into specific tubulin isotype and effects of cancer therapies may represent 
another avenue for drug therapy.    
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2.3.3 Microtubule assembly and regulation in cells 
Microtubules are assembled by stacking of the -tubulin in a head to tail orientation 
forming the dynamic polarity. When MTs assemble, the plus end grows more rapidly than the 
minus end.  MTs grow in an outward fashion, with the plus end leading, from the microtubule 
organizing center (MTOC) to the cell membrane. The minus ends remains attached to the 
MTOC. 
68
This assembly is accomplished by the hydrolysis of GTP that is associated with  
tubulin, resulting in MTs that consist primarily of GDP-tubulin stabilized at the plus end by a 
cap. 
66
 MTs assemble at temp >30 degrees C in the presence of GTP and magnesium ions and 
dis-assemble at lower temperatures.
79
 MT plus end assembly occurs by the addition of tubulin 
dimers to a sheet-like lattice that then rolls up into a cylinder as the MT grows. The growth at 
both ends is interrupted at random times by shrinkage and growth, called dynamic instability.
66, 
68, 80
 
 
2.3.4 Microtubule Dynamics: Instability and Treadmilling  
The dynamic nature of how tubulin polymerization results in spindle MTs can be 
summarized by the models of dynamic instability and treadmilling.  Dynamic instability (DI) is 
the condition in which MT ends switch between growth and shortening. There are four 
parameters within DI which include: catastrophe (transition from growth or pause to shortening), 
rescue (transition from shortening to growth or pause), pause (time in which change is 
undetectable via microscopy), and dynamicity (overall detectable rate of change via light 
microscopy). Catastrophe and rescue occur when MTs grow out from the spindle to attach to the 
chromosomes at the kinetochore. When they attach, the bipolar spindle is formed. Dynamic 
instability is an important part of the MTs function during interphase for the establishment of 
interactions between the MT spindle and the chromosomes during mitosis. During cell division 
MTs attach chromatid pairs at the kinetochore and align the chromosomes to the mid plane at 
metaphase.  Kinetochores selectively bind GTP over GDP, favoring the plus end over the minus. 
Treadmilling is the continued addition and removal of tubulin, causing a net lengthening on one 
end and a net shortening on another which results in tension on the spindle.  Tension is necessary 
for the cell to progress from metaphase to anaphase. Suppression of dynamics prevents normal 
mitotic assembly and decreases tension at the kinetochore.  Downstream, this leads to prolonged 
11 
 
mitotic arrest or apoptosis.  The cells arrest in G2/M phase.
67
 Thus, both inhibition of dynamic 
instability and treadmilling may be therapeutic targets of mitotic spindle inhibitors. 
 
2.3.5 G2/M Mitotic Checkpoint 
Chromosome alignment and segregation during cell division relies primarily on the 
interaction between the kinetochore (positive end embeds here) and the mitotic spindle.  To 
avoid errors in chromosome segregation the kinetochore must secure the spindle MTs and 
connect the sister chromatids to the opposite spindle.  MTs growing from the spindle pole search 
seek out the chromosomes.  During these movements, MTs will undergo complete catastrophe, 
shortening almost completely and then rescue and re-grow. Kinetochore movement occurs at rate 
of approximately 10-50μm/min and utilizes MT depolymerization to move toward the spindle 
poles and MT assembly to move away from the poles.  Cell cycle DNA damage check points 
occur in late G1, preventing entry into S and in late G2, preventing entry into mitosis. Regulation 
is via the Cdk protein kinases.
81
  The late G2 check point, also referred to the spindle check point 
ensures accurate chromosomal segregation. If MT dynamics are perturbed chromosomes may not 
attached or lack the appropriate tension, resulting in check point blockage of progression to 
mitosis and eventually apoptosis.
67
  Of the currently utilized chemotherapeutics, the vinca 
alkaloids and taxanes function to inhibit the G2/M transition.
62
 More than 50% of human cancers 
have dysfunctional G1 check points and rely on the G2 check point to overcome the DNA 
damage caused by most cytotoxic cancer agents.  The G2 cell cycle check point is infrequently 
utilized by normal cells, making the G2 check point an attractive target for anti-neoplastic 
drugs.
67
 
 
2.4 MICROTUBULE INHIBITORS 
As previously mentioned many naturally occurring agents inhibit MT function and have 
been used as anti-neoplastic agents for decades.  In veterinary medicine, vinca alkaloids 
originally isolated from the periwinkle Catharanthus roseus are therapeutically important for 
multiple tumor types include lymphoma, leukemia and mast cell tumors.  Broadly speaking, 
microtubule inhibitors (MTIs) are categorized as stabilizers or destabilizers.  Stabilizers such as 
taxol, docetaxol, and epithilone enhance microtubule polymerization by suppressing MT growth 
and shortening at high concentrations.  These agents bind on the inner surface of the MT. The 
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result is complete suppression of DI in the MT.
66, 67
 The destabilizers include vinca alkaloids 
(vincristine, vinblastine, vindesine and vinflunine), dolastatins and colchicine; these function to 
inhibit MT polymerization at high concentrations, leaving cells in mitosis with condensed 
chromatin. Binding of the vincristine or colchicine domain occurs on the tubulin ends at binding 
sites named eponymously. (Figure 3) Interestingly, at low concentrations both groups are capable 
of acting in the opposite manner.  With either mechanism, there is a decrease in dynamic 
movement.  The attachment to the kinetochore can be blocked and the centromere stretching and 
relaxation is decreased which will stop the cell from progressing into anaphase.
66
 
 
2.4.1 Mechanism of action: Taxanes and Vinca Alkaloids 
The taxane taxol binds poorly to soluble tubulin but binds with high affinity to tubulin 
along the interior of the MT. This binding leads to stabilization of the MT, increasing 
polymerization while decreasing the number of protofilaments. It is assumed that there is a 
resultant conformational change that increases the affinity of the neighboring tubulin.
67
 There is 
a single taxol binding site on every molecule of tubulin. In addition to MT stabilization, taxol 
increases cyclin B1 and stimulation of cdc2-B1 kinase demonstrating the multi-functional nature 
of this drug.
81
 Epithilones influence MT architecture by altering the number of protofilaments 
and influencing the lateral interactions between tubulin subunits in the neighboring 
protofilament.
68
  Taxane drug resistance occurs via the PgP drug transporter.  Epithilones have 
the advantage over taxanes in that they are not transported by a drug transporter. 
67
 The vinca 
alkaloids’ destabilizing effect results from the poisoning of the tubulin heterodimer. It is believed 
to prevent polymerization from occurring by blocking the region involved in heterodimer 
attachment. This has earned the vinca alkaloids the name “mitotic spindle poisons”.  Vinblastine 
binds to tubulin and directly to the MT at β tubulin via the vinca domain. Binding is rapid and 
reversible and induces a conformational change that leads to tubulin self-association.  Drug 
resistance with vincristine and vinblastine is primarily due to PgP protein and MDR gene.
82
 All 
MT targeted drugs have the ability to suppress MT growth resulting in decreased dynamicity and 
suppression which is adequate to prevent progression of mitosis. Both taxol and the vincas 
inhibit the stretch and relaxation that must occur between centrosomes of the paired chromatids 
to allow for separation and progression through cell division.  
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Vinca alkaloids and colchicine also have anti-proliferative effects on tumor vasculature. 
This effect has been seen a doses much lower than the MTI effects. Microtubule targeted 
vascular disruption has been under heavy investigation and colchicine-like drugs are in clinical 
trials (Auristatin PE and Trisenox).
67
 This additional mechanism may allow MTIs to be used as 
anti-angiogenic and/or vascular-disrupting agents as well, allowing for additional mechanisms of 
action. (Table 2) Therapies that utilize multiple targets to promote cytotoxic effects may provide 
improved efficacy.  
 
2.5 ANGIOGENESIS 
Angiogenesis is the formation of new blood vessels from existing vascular structures. It is 
a key step in both tumor growth and the development of metastasis and plays a vital role in 
embryonic and post-natal development, menstruation and wound healing. Primary tumors as well 
as metastatic foci require oxygen and nutrient transport necessitating sustained angiogenesis. 
Capillaries must be within a distance of 1-2mm to ensure that cells receive appropriate oxygen 
and nutrients.
83
  In malignant angiogenesis, continuous stimulation by the tumor and stromal 
cells is required to support new growth.
84
 If new vessel growth cannot keep up with the rapid 
growth rate of the tumor, hypoxia ensues and the tumor can become necrotic. This condition of 
oxygen deprivation is an important trigger for tumor vessel growth.  There are more than a dozen 
endogenous proteins that can act as positive regulators or activators of tumor angiogenesis. A 
hypoxic environment stabilizes hypoxia-inducible factor-1(HIF-185  HIF-1 is the primary 
transcriptional regulator of VEGF.  HIF-1also regulates other target genes: pro-angiogenic 
cytokines such as fibroblast growth factor-3 (FGF-3) and hepatocyte growth factor (HGF), 
transcription factors such as annexin V, insulin-like growth factor binding proteins 1,2 and 3 and 
heat shock factor, and various integrins and matrix metalloproteinases.
86
 Angiogenesis can be 
promoted both by pro-angiogenic cytokines such as VEGF secreted from neoplastic and 
inflammatory cells as well as upregulation of pro-angiogenic receptors such as VEGFR.  
Additional important regulators of angiogenesis include tumor necrosis factor α (TNF-α), basic 
fibroblast growth factor (bFGF), angiopoietin-1 and angiopoietin-2, interleukin-8 (IL-8), and 
platelet-derived growth factor β (PDGF-β).85, 87, 88 Pro-angiogenic factors are balanced by the 
major anti-angiogenic/inhibitory factors including angiostatin, endostatin, interferon-α, and 
interferon-β.88 
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For new vessels to develop, vasodilation and increased vascular permeability must occur. 
Endothelial cells become activated and migrate through the basement membrane.  The milieu of 
activated cytokines promotes signaling and survival of these endothelial cells. The cells invade 
the extracellular matrix (ECM) and begin to form tubular structures.  Subsequent re-organization 
of the ECM helps to support the newly formed tubular structures.
88
 
The single most important factor in angiogenesis is vascular endothelial growth factor 
(VEGF-A/VEGF).  VEGF, a selective mitogen for endothelial cells, increases microvascular 
permeability and leakage.  Although necessary for normal development and wound healing, 
VEGF overexpression has been demonstrated in tumors across species and is associated with 
malignant angiogenesis.  VEGF also increases malignant cell trans-endothelial migration in 
vitro.
86
 Serum VEGF levels are elevated in dogs with osteosarcoma and pretreatment elevation is 
correlated with disease free interval. 
10
In people, overexpression of VEGF is linked to disease 
progression and poor prognosis in various carcinomas as well as osteosarcoma. Thus, VEGF 
may be useful both a surrogate biomarker of drug biologic activity as well as a target for therapy. 
Another potential surrogate biomarker of anti-angiogenic therapy is tumor hypoxia.  Direct 
tumor hypoxia can be measured by the use of a probe to measure oxygen concentration within 
the tumor, or in a surrogate manner using endogenous markers such as HIF-1  or exogenous 
probes (pimonidazole and EF5). In human cancer patients, tumor hypoxia may have prognostic 
and predictive significance.
89
 
 
2.5.1 Assessment of angiogenesis 
Microvessel density (MVD) has historically been the standard method used to 
quantifying tumor vascularity in tumor tissue. Immunohistochemistry with CD31 or von 
Willebrands factor can be performed to detect endothelial cells.  Based on the number of blood 
vessels in a unit of area, called the vascular hotspot, a MVD score can be determined.
90
 In people 
a strong correlation between MVD and outcome has been identified in carcinomas such as 
breast, gastric, colorectal and prostatic. MVD has been suggested as a prognostic factor in some 
human studies, and has been suggested as a prognostic factor in canine osteosarcoma.
9192
Newer 
methods to assess tumor vascularity in vivo include various imaging modalities such as dynamic 
contrast-enhanced magnetic resonance imaging (DC-MRI), dynamic contrast-enhanced 
computed tomography (DC-CT), positron emission tomography (PET), single-photon emission 
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computed tomography (SPECT), optical imaging, and microbubble contrast-enhanced 
ultrasound.
93, 94, 95, 96
 Serum biomarkers are another surrogate method of assessing angiogenesis 
in vivo.  The advantage of using biomarkers are that they are non-invasive, simple and represent 
current status within the patient, quantitative, and relatively inexpensive; however serum levels 
may not accurately reflect the tumor microenvironment. The use of these modalities may also be 
valuable for monitoring response to therapy as the clinical use of anti-neoplastic drugs with anti-
angiogenic properties increases. 
 
2.5.2 VEGF-Structure and Function 
Vascular endothelial growth factor (VEGF/ VEGF-A) is 45-47kD glycoprotein that is a 
specific mitogen for endothelial cells. It belongs to the VEGF/PDGF (platelet derived growth 
factor) cysteine-knot superfamily and is a tyrosine kinase receptor ligand. This superfamily is 
important in hormone and extracellular signaling molecule formation in eukaryotes. 
97, 98
 VEGF 
is produced from a DNA coding region (human chromosome 6p21.3) with eight exons.  VEGF is 
highly conserved across species. At least six human isoforms (121, 145, 165, 183, 189, 206 
amino acids) exist as a result of alternative splicing of the mRNA.
99, 100
 (Figure 4) Alternative 
splicing is vital in regulating the bioavailability of VEGF. Most VEGF producing neoplastic cells 
preferentially express VEGF 121, VEGF 165 and VEGF 189. These three major isoforms of 
VEGF have different properties concerning receptor binding and extracellular localization. 
Isoform 121 is the shortest and most freely diffusible.  Isoform 165 has the highest mitogenic 
efficacy, while 189 is primarily extracellular membrane-associated.
101, 102
 The more soluble 
isoforms acts at distal sites to promote vascular recruitment, and the extracellular membrane-
associated isoforms promote local expansion of capillary beds.  VEGF is key in promoting 
normal physiologic as well as pathologic angiogenesis. VEGF has many effects including 
induction of proteases that cause extracellular matrix remodeling, increase in vascular 
permeability, and endothelial cell migration and growth. VEGF activates the VEGFR-1 (Flt-1) 
and VEGFR-2 (Flk-1 or KDR) receptors on human endothelial cells and the VEGFR-2 receptor 
in dogs.
8, 103
 VEGF works via inhibition of apoptosis, cell proliferation, sprouting, migration tube 
formation and increased vascular permeability.  All of this occurs through the interaction of 
VEGF with its tyrosine kinase receptors.  The mitogenic, angiogenic and permeability-enhancing 
effects of VEGF are primarily due to VEGFR-2. 
22
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2.5.3 VEGF: Regulation  
It is believed that VEGF works in a paracrine fashion via the heparinase driven release of 
the various isoforms that are found on the cell surface or extracellular matrix.
100
As previously 
noted, the major transcriptional regulator of VEGF is HIF-1.  In normoxic conditions, HIF-1, a 
transcription factor comprised of an and subunit is hydroxylated, bound by von-Hippel 
Lindau (VHL)/ubiquitin complex, and targeted for ubiquitin degradation. In hypoxic conditions 
(such as the tumor microenvironment) HIF-1transcription is activated and is protein stabilized 
which results in active HIF-1 complex formation and subsequently increased VEGF 
transcription.
85, 104
 (Figure 5)   
Tumors often modulate VEGF expression through transcriptional regulation.  VEGF 
expression has been correlated to high mitotic activity and cell proliferation.
22
 VEGF receptors 
are also overexpressed in many tumor types in both people and dogs (OSA, gastric, esophageal, 
breast, renal, lung and colorectal carcinomas).
8, 103
  Hypoxic induction of HIF-1α, subsequently 
elevated VEGF expression, and increased MVD have been documented in human OS, indicative 
of a more aggressive phenotype and higher rate of metastasis.
91, 105
 As previously discussed 
oxygen tension is highly important in the regulation and expression of VEGF mRNA via HIF-
1Potential tumor-associated regulators of VEGF expression include various growth factors 
(EGF, TGF- TGF-, FGF and PDGF), the inflammatory cytokines IL-1 and IL-6, and  
amplification or oncogenic mutations of Ras.
106
 VEGF protein levels are highly influenced by 
post-transcriptional changes. The half-life of VEGF mRNA is under one hour, making regulation 
of its stability a priority. The principal method of post-translational regulation is N-linked 
glycosylation, which promotes protein secretion.  VEGF undergoes N-linked glycosylation 
(fucosylation) at a specific asparagine residue. Non-glycosylated VEGF isoforms suffer from 
inefficient secretion and exhibit lower heparin binding affinity.
100, 101
 The mechanism by which 
microtubule inhibitory drugs exert their effects on VEGF has not been well described.  
Microtubules regulate HIF-1via control of mRNA transport and ensuing HIF translation.   
Taxanes and other MT disrupting agents inhibit nuclear accumulation of HIF-1. HIF-1can 
be included with other transcription factors that utilize microtubules for transport during 
interphase.  As HIF-1is regulated by MTs at both protein synthesis and trafficking levels, the 
efficacy of the MT inhibitors may be more significant than previously understood. 
107
  Inhibition 
of protein synthesis and/or trafficking of both HIF-1and/or VEGF may be potential 
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mechanisms by which MTIs, and possibly BZs, modulate VEGF levels.  Further investigation is 
needed in this area.  
  
2.5.4 VEGF: Receptors 
Tumors may also promote angiogenesis by up regulating VEGF receptors, specifically 
VEGFR-1 (flt-1), VEGFR-2 (flk-1/KDR), and less importantly heparin sulfate proteoglycans, 
and neuropilins. 
100
 The VEGF receptors are structurally similar, having an extracellular ligand-
binding region comprised of seven immunoglobulin-like loop domains attached with a short 
trans-membrane helix to a cytoplasmic catalytic domain.   VEGFR-1 is expressed on both 
endothelial cells and monocytes while VEGFR-2 is limited to the endothelium. 
108
 VEGF is 
secreted by nearly all solid tumors in response to hypoxia.  Upregulation of VEGF has been 
clearly demonstrated in human cancers and more recently in various canine tumors.
103, 109
 In 
canine mammary gland tumors increased VEGF and VEGFR-2 were strongly correlated with a 
high histologic grade and tumor proliferation. 
110
 VEGF, VEGFR 1 and 2 staining is significantly 
stronger in hemangiosarcomas compared to hemangiomas, indicating that even in vascular 
tissues, the neoplastic process causes upregulation of VEGF and its receptors.
111
VEGFR-2 links 
with candidate genes associated with poor prognosis in canine OS on pathway analysis.
112
 
 
2.5.5 VEGF: Inhibitors 
Many anti-angiogenic and anti-vasculogenic drugs exist. Some inhibit endothelial cells 
directly while others inhibit the signaling cascade or impair the ability of endothelial cells to 
break down the ECM. Specific targeting of VEGF involves prevention of ligand-receptor 
interaction through ligand sequestration with a VEGF antibody, competitive inhibition of kinase 
activity or blocking the binding of VEGF-A with a monoclonal antibody to the receptor.
113
 
(Figure 6) One of the few FDA approved and best known VEGF inhibitors used in human 
medicine is bevacizumab (Avastin). Bevacizumab is a humanized monoclonal antibody that 
targets VEGF-A in the treatment of various cancers, including colorectal, lung, breast, kidney, 
and glioblastoma.
108, 114
  Antibody therapy in veterinary medicine is lacking due to cost of 
development and functionality, however tyrosine kinase inhibitors (TKIs) have gained 
significant popularity over the last decade. TKIs work by blocking (reversibly or irreversibly) the 
ATP binding site of a kinase.  If ATP cannot bind, the kinase cannot phosphorylate itself or 
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initiate downstream signaling.
98
VEGF, PDGRF and FGFR are members of the receptor tyrosine 
kinase family and their blockade prevents both auto-phosphorylation and signal transduction 
thereby stopping the angiogenic signal. (Figure 6) The advantage of a TKI is twofold in that it is 
effective against cancers that have upregulation of VEGF and/or VEGF receptors.  The TKIs as 
small molecule inhibitors have been very successful as anti-cancer therapies both alone and in 
combination with tradition cytotoxic therapies.  Some BZs also exhibit tyrosine kinase inhibition 
and this may be another mechanism of therapeutic activity in addition to MTI.  ABZ appears to 
inhibit VEGF in malignant ascites formation
115
 
116
 and more recently, a series of novel BZ 
derivatives have been shown to inhibit various growth factor receptors (EGFR, VEGFR-2 and 
PDGFR).
38
 The molecular mechanism of these actions has not been well described.  Further 
investigation into optimal anti-cancer BZ drug/dose as well as elucidation of the mechanism by 
which they inhibit tumor growth may open the door to a novel adjunctive therapy. 
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CHAPTER 3 
 IN VITRO EFFECTS OF BENZIMIDAZOLES ON 
THE CANINE OSTEOSARCOMA CELL LINE D17 
 
3.1 INTRODUCTION 
Canine osteosarcoma (OS) is a naturally occurring tumor that is highly malignant and 
causes severe pain in affected patients. The disease is considered nearly universally fatal in dogs. 
From a comparative oncologic standpoint the dog is an excellent model for human OS as it 
follows a similar clinical course, and effective treatment is hampered by challenges similar to 
those encountered in human medicine.  Additional therapeutic options could not only improve 
the quality of life and survival in canine patients but may also contribute to the treatment of bone 
tumors affecting people. Novel therapeutic options for the treatment of canine OS have been 
limited over last two decades and in the quest for new agents we look to agents that exhibit both 
direct cytotoxicity as well as indirect effect on molecular targets such as vascular endothelial 
growth factor (VEGF).  One avenue in investigating novel therapies is re-purposing of existing 
drugs with known toxicity profiles for their putative anti-cancer activity as a prudent use of 
limited research resources.   
The benzimidazoles (BZs) are known microtubule (MT) inhibitors that have resurfaced 
as more than just anti-parasitics in both human and veterinary medicine.  In vivo rodent work had 
initially shown promise for the BZs as anti-neoplastic agents and some engineered BZs are now 
in clinical trials for people.
34
  It is believed that the BZs have both direct and indirect anti-
neoplastic effects; the direct effects through MT inhibition
117
 leading to growth arrest, and 
indirect effects via angiogenesis modulation.
18-21
 Modulation of angiogenesis appears to 
primarily function through reduction in VEGF, a selective mitogen for endothelial cells that 
increases microvascular permeability and leakage. Microtubule inhibitors are a current mainstay 
class of anti-neoplastic drugs in both human and veterinary medicine.  Pediatric OS is treated 
with paclitaxel and docetaxel 
23, 118-120
 and the vinca alkaloids and taxanes are used for the 
treatment of various tumors in veterinary medicine.   Alteration of MT polymerization causes 
cell arrest in telophase, triggering apoptosis.  Canine OS is an attractive in vitro tumor model for 
testing the effects of novel MTIs such as BZs based on reported sensitivity to MT inhibitors 
1-3 
and the in vivo role of VEGF in angiogenesis and tumor progression. 
9, 10
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The hypothesis of this study was that BZs exert direct and indirect anti-cancer activity in vitro in 
canine osteosarcoma.  Our objectives were to: 
1.  Investigate the direct in vitro anti-neoplastic effects of BZs on cell proliferation and apoptosis 
in a canine OSA cell line (D17).   
2.  Demonstrate that a primary mechanism of action of BZs is direct MT inhibition leading to 
cell cycle arrest in G2/M in D17 cells. 
3.  Investigate the effects of BZs on VEGF secretion from D17 cells (addressed in the next 
chapter).    
 
3.2 MATERIALS AND METHODS 
3.2.1 Cell lines 
A canine osteosarcoma cell line (D17) was purchased commercially from American 
Tissue Culture Collection (Manassas, VA).  Cells were cultured in Dulbecco’s modified eagle 
medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cell 
cultures were maintained at 37 °C in 5% CO2 and passaged twice weekly. 
 
3.2.2 Reagents  
Albendazole (ABZ), fenbendazole (FBZ) and mebendazole (MBZ) was obtained from 
Sigma Aldrich. Stock solutions were prepared in DMSO prior to each use.  At the highest drug 
concentration used for experiments, vehicle was 1% DMSO (used for vehicle control).  
 
3.2.3 In vitro cell proliferation  
D17 cells were plated at a density of 7.5 x 10
4
 cells per 200 µl of complete media in a 96-
well microtiter plate incubated at 37°C and 5% CO2.  After allowing cells to adhere for 24 hours, 
media was decanted and replaced with fresh media containing various concentrations of ABZ, 
FBZ and MBZ (0 -200µM).  Following 24 and 48 hours of BZ treatment, adherent cells in 
microwells were washed twice with PBS.  The plate was analyzed for cell proliferation using a 
tetrazolium salt-containing colorimetric cell proliferation assay (CellTiter 96® AQueous One, 
Promega Corporation, Madison, WI) after 100 μL of fresh medium was added to each well. 
Briefly, the assay uses a MTS tetrazolium compound that is bioreduced by metabolically active 
cells into a colored formazan product that is soluble in tissue culture medium. Formazan as 
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measured by the absorbance at 490nm is directly proportional to the number of living cells.  
Results are expressed as percentage of viable cells compared to untreated cells.   Dose response 
curves were used to calculate IC50 for all drugs.  
 
3.2.4 In vitro flow cytometry for apoptosis and cell cycle distribution 
To evaluate the effects of BZs on cell viability, apoptosis was measured via flow 
cytometry.  D17 cells were initially plated at a density of 1 x 10
5
 cells per T25 tissue culture 
flask in complete media and incubated at 37°C and 5% CO2. Cells were then grown in 6 well 
plates.  After allowing cells to adhere for 24 hours, media was decanted and replaced with fresh 
media containing various concentrations of ABZ, FBZ and MBZ (0-25µM). Cells were allowed 
to grow for an additional 24 hours in the presence or absence of drug.  D17 cultures were 
trypsinized, harvested and washed once in phosphate-buffered saline (PBS) and resuspended in 
1X binding buffer in PBS.  Apoptosis was assessed by flow cytometry using the Annexin V-
FITC apoptosis detection kit as described by the manufacturer (BD Biosciences Pharmingen, San 
Diego, CA). Cells were incubated with Annexin V-FITC in the dark at room temperature for 30 
minutes. Cells were then washed once with PBS and re-suspended in 1X binding buffer in PBS 
supplemented with propidium iodide (PI).  Flow cytometry data was acquired with the BD 
Accuri ® C6 flow cytometry machine and cells were gated based on their forward and side 
scatter properties.   Cells were determined to be viable, early apoptotic, late apoptotic, and 
necrotic based on absolute Annexin-V-FITC and PI staining. Annexin V-FITC binds to 
phosphatidylserine located on the outer leaflet of the cell membrane.  In a normal cell the 
phosphatidylserine is located on the inner leaflet of the membrane and in the event of early 
apoptosis, the phosphatidylserine moves to the outer leaflet.  Propidium iodide (PI) is a vital dye 
that is excluded by intact cell membranes. Propidium iodide binds to DNA by intercalation 
between bases and may be used to assess cell membrane integrity with Annexin V. It can also be 
used to label late apoptotic cells as they have already lost their membrane integrity as well as to 
evaluate DNA content for cell viability.  All data were analyzed using FACS (DeNovo 
Software).  A minimum of 100,000 cells were counted for each sample.  Triplicates of each 
experimental condition were performed. 
To evaluate the effects of BZs on cell cycle distribution, flow cytometry with PI was 
performed. After drug treatment, cells were harvested, washed twice with PBS, and re-suspended 
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to total volume of 1 mL of 70% ice-cold ethanol overnight at -20°C. The cells were washed 
twice in PBS, centrifuged, and the pellets were re-suspended in a total volume of 200 μL PBS 
containing RNase A (5μg) and PI (10 μg).  Parameters including forward and side scatter and 
DNA content were obtained using a BD Accuri ® C6 flow cytometer.  A 488 nm (blue laser) 
was used with a 585/40 filter for PI excitation/emission.  FACS Express 4.0 (DeNovo Software) 
was used for gating and analysis of cell cycle using single cycle assessment of the diploid cells. 
A minimum of 12,000 cells were counted per sample.   Triplicates of each experimental 
condition were performed. 
 
3.2.5 In vitro tubulin polymerization 
To evaluate the effects of BZs on tubulin polymerization necessary for MT assembly, a 
porcine brain tubulin polymerization assay was performed in 100-μl volumes at 37°C using a 
commercial assay (Cytoskeleton, Denver) according to the manufacturer's instructions. In brief, 
10 μL of sample (drug or control ) in G-PEM buffer [80 mmol/L PIPES, 2 mmol/L MgCl2, 0.5 
mmol/L EGTA, 1 mmol/L GTP (pH 6.9), 5% (v/v) glycerol] were added to a 96-well plate and 
incubated at 37°C for 10 minutes. Then, 100 μL of 3.0 mg/mL reconstituted tubulin in G-PEM 
buffer at 4°C were pipetted into each well. The plate was incubated in a plate reader at 37°C and 
the absorbance was recorded immediately. The effects on polymerization of the test compounds 
were quantified by measuring the absorbance every 30 seconds at 340 nm (A340) for 60 minutes 
using a FLUOStar® Optima reader (BMG Labtech, Durham NC) was used to acquire data using 
the kinetic mode (two readings per minute).  Duplicates of each experimental condition were 
performed and averaged.  
 
3.3 STATISTICAL ANALYSIS 
Normal distributed data sets were expressed as mean and standard deviation, and non-
normal distributed data sets were expressed as median and range. All statistical analysis was 
performed using commercial computer software (GraphPad, Instat3). Significance was defined 
as p < 0.05. 
For each drug, cell proliferation as assessed by change in cell count in treated and vehicle 
control (1% DMSO) cells in comparison to untreated cells (media control) was analyzed with a 
one-way ANOVA with Dunnett’s post-hoc test.  Apoptosis as assessed by Annexin-FITC mean 
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fluorescent intensity in comparison to untreated (media control) cells was analyzed with a one-
way ANOVA with Dunnett’s post-hoc test.  Cell cycle arrest as assessed by percent of cells in 
G2/M phase in comparison to untreated (media control) cells was analyzed with a one-way 
ANOVA with Dunnett’s post-hoc test.   
 
3.4 RESULTS 
3.4.1 In vitro cell proliferation  
 All BZs induce a dose dependent and time dependent effect of cell proliferation 
compared to untreated media control.  Vehicle control (1% DMSO) was not statistically different 
from untreated media control.  For ABZ at 24hr incubation, p<0.01 for drug dose ≥5μM with a 
25% inhibition of cell proliferation.  There is a possible trend towards significance at 1μM 
(p=0.06).  For MBZ at 24hr incubation, p<0.01 for drug dose ≥5μM, with a 24% inhibition of 
proliferation.   For FBZ at 24hr incubation, p<0.01 for drug dose ≥5μM, with a 20% inhibition of 
proliferation.  (Figures 7-10) The effect on cell proliferation is even greater after a 48 hour drug 
incubation period (data not shown). IC50 for BZs was calculated at 23.4 μM for ABZ, 17.5μM 
for MBZ, and 79.1 μM for FBZ.   
 
3.4.2 In vitro flow cytometry for apoptosis and cell cycle arrest 
 Flow cytometric analysis of cells labeled with Annexin V-FITC demonstrated induction 
of apoptosis for all drugs.  Vehicle control (1% DMSO) was not statistically different from 
untreated media control.  Figure 11 depicts representative histograms for MBZ; all results were 
similar.  There was efficacy at all doses ranging from 1.6 µM to 25 µM for all three BZs.  Effects 
are dose-dependent with the high dose of 25 µM demonstrating a mean of nearly 33% of cells 
apoptotic when treated with FBZ, 22% with MBZ and 9% with ABZ.  ABZ was least effective in 
inducing apoptosis, with apoptotic cells doubling compared to control at doses of ≥12.5 µM 
while apoptotic cells more than doubled compared to control at doses of ≥1.6 µM. (Figure 12, 
Table 3)   
Flow cytometric analysis of cell cycle distribution demonstrated cell cycle arrest for all 
drugs.  The histograms visually demonstrate the re-distribution between G1, S, and G2/M 
phases. (Figure 13)   The gates depicted in Figure 13 were selected manually and are for visual 
demonstration only.  Actual calculations were performed using the FACS Express 4.0 software 
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which more accurately calculates the true S phase component using mathematical modeling. 
(Figure 14) For all samples, no abnormal DNA content was noted and the S phase confidence 
was fair to good.  For MBZ and FBZ, cells were predominantly (>80%) arrested in G2/M at 
doses of ≥1 µM (p<0.01).  ABZ showed a slightly less robust response, with 51% of cells 
arrested in G2/M at ≥1 µM and >80% of cells arrested in G2/M at higher doses ((p<0.01).  
(Figure 15, Table 4)  
 
3.4.3 In vitro microtubule polymerization 
Evaluation of the effect of ABZ, FBZ and MBZ on tubulin polymerization showed a dose 
independent inhibition of polymerization.   Controls included no drug treatment (baseline 
polymerization), paclitaxel (1μM) a polymerization stabilizer (taxane), and vincristine (2μM) as 
a polymerization destabilizer (vinca alkaloid).  Visually, there is an apparent difference in rate of 
polymerization between controls.  To compare the curves of treatment groups to control, we used 
the slopes method in which the rate of polymerization is obtained graphically from the linear 
portion of the polymerization profile, which represents the elongation phase of microtubule 
assembly. (Figure 16)  Drug treatments visually produce polymerization curves fitted between no 
drug treatment and the polymerization destabilizer vincristine.  The depolymerization of the 
various treatments was calculated by comparison to control and vincristine.  The difference 
between no drug treatment and vincristine was set as maximal depolymerization, or 100% 
depolymerization effect.  Effects of drug treatment on depolymerization were compared to this.  
There was no apparent dose-dependent effect for any drug, in fact for all drugs, minimal 
response was seen at the highest dose of 50μM.  The most robust response was seen with ABZ: 
doses of 10-25 μM demonstrated increased depolymerization compared to vincristine (128-160% 
of maximal response) while at a higher dose of 50μM, there was slightly less effect at 88%.  
(Figure 17) The least response was seen with FBZ: doses of 10-25 μM demonstrated modest 
depolymerization compared to vincristine (42-59% of maximal response) while a higher dose of 
50μM demonstrate no effect and was similar to no drug (2.3% maximal response). (Figure 18)  
Mebendazole had similar and less robust response compared to ABZ, with doses of 10-25 μM 
demonstrated slightly increased depolymerization compared to vincristine (111-123% of 
maximal response) while at a higher dose of 50μM, there was slightly less effect at 64%. (Figure 
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19)  Our data confirm that all three BZs do function as MT inhibitors via destabilization similar 
to vincristine. (Figures 16-19) 
 
3.5 DISCUSSION 
Benzimidazoles have been shown to have direct anti-neoplastic effects on cancer cells by 
inhibiting cell proliferation and inducing apoptosis. These effects have been well documented in 
both animal and human cancers. 
14, 53, 55, 56, 121
 Our in vitro results in the D17 OSA cell line 
demonstrate that all BZs tested do inhibit cell proliferation and that the cells undergo apoptosis 
following cell cycle arrest in G2/M. Proliferation was inhibited at doses of 5μM and above for all 
BZs, with the least response to FBZ treatment.  Apoptosis was identified at similar 
concentrations, with BZ treatment ≥1.6 μM resulting in increased apoptosis.   The apoptotic 
effect was most pronounced with MBZ and FBZ as compared to ABZ.  Based on PK data for 
ABZ and FBZ all treatment doses from 1uM to 25 μM are biologically achievable (with oral 
doses of 20-125mg/kg/day) and are documented as well tolerated. Typical anti-parasitic doses 
are 25-50 mg/kg every12 hours for ABZ and every 24 hours for FBZ. Only ABZ at the higher 
doses for 25 μM and above have been documented to cause mild gastrointestinal upset.  36, 41, 46 
While PK data for MBZ is not reported in dogs, we can only speculate as to whether these doses 
would be physiologically achievable in the dog. Based on similar chemical characteristics, 
bioavailability and molecular weight, we believe this a reasonable assumption.  Flow cytometry 
confirmed that the inhibition of proliferation in these cells was not due to cellular necrosis and 
that the mechanism is G2/M arrest by MT inhibition.  The least response was seen with ABZ at 
1μM, however all other drug concentrations were similar with >80% cell cycle arrest.  A dose 
dependent response may be present but would necessitate investigation of very low doses (≤1 
μM BZ). The finding that cells arrested in G2/M supports the mechanism of microtubule 
inhibition.  When microtubule polymerization is altered, the normal tension and relaxation of the 
kinetochore is absent.  This is a critical signal to the cell and cellular arrest ensues. 
Polymerization assays confirmed the effect of all three BZs on polymerization inhibition.  This 
effect was rapid, independent of dose and nearly identical between all drugs. Interestingly, at low 
concentrations both vinca alkaloids and taxanes are reported to act in an opposite manner at the 
microtubule; 
66
 perhaps BZs exhibit similar changes with concentration.  Further investigation at 
additional concentrations would be needed to evaluate this.   
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Limitations of the study include the in vitro nature of these results, which may not be 
representative of naturally occurring disease. These are preliminary findings on the effects on 
cellular proliferation, microtubule inhibition and resulting cellular arrest and apoptosis. Effects 
appear to be dose-dependent except for tubulin polymerization.  While all three BZs exhibited 
some effects, ultimately FBZ appears least effect overall. All three drugs exhibit similar G2/M 
cell cycle arrest.  FBZ had the least effect on cellular proliferation and tubulin depolymerization.  
MBZ and ABZ have comparatively similar profiles, however ABZ appeared least effective at 
inducing apoptosis and demonstrated slightly reduced effect on cell cycle distribution at a low 
dose.   
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CHAPTER 4 
IN VITRO EFFECTS OF BENZIMIDAZOLES ON 
VEGF SECRETION IN D17 CELLS 
 
4.1 INTRODUCTION 
Osteosarcoma (OS) is a highly malignant and severely painful disease that affects both 
people and dogs. Aggressive treatment with amputation and chemotherapy has improved comfort 
and survival.  Ultimately, 90% of dogs will die from metastatic disease with an average of one 
year survival despite aggressive therapy, underscoring the negative effects of occult micro-
metastatic disease at the time of diagnosis. While maximum tolerated dose chemotherapy with 
drugs such as doxorubicin and carboplatin delay metastasis, little has been achieved over the last 
two decades to significantly extend overall survival times.  The long-term prognosis for dogs 
with OS is poor and thus novel adjuvant therapies which slow tumor growth (anti-angiogenic 
therapies) may be beneficial in combination with direct cytotoxic drugs.  
Angiogenesis is necessary for continued primary tumor growth as well as establishing 
distant metastases. 
88, 100, 122
Regulation of angiogenesis is primarily by vascular endothelial 
growth factor (VEGF). Given that sustained angiogenesis is necessary for tumor growth, 
therapeutic strategies which reduce or block the effects of tumor associated VEGF are currently 
being investigated for the treatment of various cancers and have improved survival in many 
cancers and may help to delay progression of micro-metastasis, which could significantly 
improve survival times of OSA. Serum VEGF levels are elevated in dogs with OS and 
pretreatment levels have been significantly correlated with disease free interval. In humans, 
overexpression of VEGF is linked to progression of disease and poor prognosis in carcinomas as 
well as OS. 
7, 10
  Based on osteosarcoma’s sensitivity to microtubule inhibitors as well as the 
association with VEGF overexpression, investigation of putative BZs indirect effects via VEGF 
modulation are warranted. 
 The benzimidazoles are a class of anti-parasitics and anti-fungals that exert in vivo and in 
vitro anti-neoplastic effects.  In one study, the discovery of the anti-neoplastic effects of FBZ 
was incidental and serendipitous, when rodents treated with routine FBZ dewormer experienced 
xenograft tumor failure. 
13
Many synthetic BZ have been manufactured and these have been 
utilized more in human medicine for both antifungal and more recently anti-neoplastic effects 
14, 
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123
 Additionally, several BZ derived compounds including ABZ have been shown to decrease 
VEGF secretion and microvessel formation. 
124, 125
 The advantages of the BZs for veterinary 
medicine are their long established use, wide margin of safety and low cost.   
The purpose of this study was to investigate the in vitro effects of ABZ, FBZ and MBZ 
on VEGF secretion in an immortalized canine osteosarcoma cell line, D17.  In light of 
microtubule inhibition, an observed decrease in VEGF may be due to the MTs role in protein 
synthesis and trafficking, perhaps at the level of HIF1-α or VEGF transcription and translation.  
Further investigation would be needed to investigate anti-angiogenic molecular mechanisms 
further.  
 
4.2 MATERIAL AND METHODS 
4.2.1 Cell lines 
A canine osteosarcoma cell line (D17) was purchased commercially from American 
Tissue Culture Collection (Manassas, VA).  Cells were cultured in in Dulbecco’s modified eagle 
medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cell 
cultures were maintained at 37 °C in 5% CO2 and passaged twice weekly. 
 
4.2.2 Reagents and antibodies 
Albendazole (ABZ), fenbendazole (FBZ) and mebendazole (MBZ) was obtained from 
Sigma Aldrich. Stock solutions were prepared in DMSO prior to each use.  A commercial canine 
ELISA (Canine VEGF DuoSet, R&D Systems) was used to quantify soluble VEGF.  The kit was 
used as per manufacturer’s instructions. 
 
4.2.3 In Vitro VEGF Secretion 
D17 cells were plated at a density of 7.5 x 10
3
 cells per 200 µl of complete media in a 96-
well microtiter plate incubated at 37 °C and 5% CO2. After allowing cells to adhere overnight, 
media was decanted and replaced with fresh media containing various concentrations of ABZ, 
FBZ and MBZ (0-200µM), and cells were allowed to grow for an additional 24 hours. Cell 
culture supernatants (in triplicate) were harvested and soluble VEGF determined with a 
commercially-available immunoassay (Canine VEGF DuoSet, R&D Systems). Differences in 
soluble VEGF secreted by D17 subsequent to treatment with BZs were normalized based upon 
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differences in cell proliferation through the use of a non-radioactive colorimetric proliferation 
assay (CellTiter96) in which optical density linearly correlates with viable cell numbers. 
(Described in Chapter 3) Specifically, normalized VEGF concentrations were based the average 
of triplicate samples for each experimental group expressed as the following ratio: 
Normalized VEGF = [Calculated VEGF (pg/ml)]/optical density 
 
4.3 STATISTICAL ANALYSIS  
To assess the dose-dependent, biologic activity of ABZ, FBZ and MBZ in the D17 OS 
cell line, reductions in soluble VEGF secretion (normalized based on paired proliferation assay 
OD) were evaluated with a one way ANOVA with Dunnett’s post-hoc test.  Normally distributed 
data sets were expressed as mean and standard deviation. All statistical analysis was performed 
using commercial computer software (GraphPad, Instat3). Significance was defined as p < 0.05. 
 
4.4 RESULTS 
4.4.1 In Vitro VEGF Secretion 
All BZs induce a dose dependent effect of VEGF secretion compared to untreated media 
control.  Vehicle control (1% DMSO) was not statistically different from untreated media 
control.  MBZ appeared to have the most robust response, with significant inhibition of VEGF 
secretion in D17 cells at doses ≥1μM (p<0.01) and ~50% reduction at doses ≥1μM.  ABZ 
significantly inhibited VEGF secretion in D17 cells at doses ≥1μM (p<0.01), with >50% 
reduction at doses ≥10μM.  FBZ was least effective, with significant inhibition of VEGF 
secretion in D17 cells at doses ≥5μM (p<0.01) and slightly less than 50% reduction at doses 
≥50μM. (Figures 20-23) 
 
4.5 DISCUSSION 
Our results show that all three BZs decreased VEGF secretion in the D17 OS cell line.  
Fenbendazole had limited effectiveness in reducing VEGF secretion. While our results indicate a 
decrease in VEGF levels the underlying mechanism is unknown.  Microtubules may play a role 
in protein accumulation and transcription HIF 1-, the upstream regulator of VEGF; however it 
would be erroneous to assume this to be the most important mechanism.  Further investigation is 
ongoing to evaluate VEGF and HIF 1- protein expression via Western blot to elucidate where 
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in the pathway VEGF protein is modulated. In light of the significance of VEGF levels in 
predicting and tumor recurrence in various tumors including canine OS, the BZs effect on VEGF 
secretion may be auspicious to their other anti-neoplastic effects 
7, 10
 A drug that has both anti-
proliferative, apoptotic and anti-angiogenic effects could be a useful addition in our treatment 
protocols for OS and possibly other tumors. Further investigation into the exact mechanism of 
VEGF inhibition is needed.  Although the predictive value of this in vitro data is limited, 
evaluation of serum VEGF as a surrogate of BZ drug effect would be reasonable to determine in 
pilot studies in vivo.   
Limitation of our study includes the use of a single OS cell line and a single read-out of 
angiogenic effect. This cell line may not be representative of all OSs or correlate with biologic 
effects in naturally occurring disease.  Soluble VEGF may not be the major anti-angiogenic 
mechanism, and may not translate into a biomarker in vivo as global serum levels may not reflect 
the tumor microenvironment. 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
In this study we present data to support that ABZ, FBZ and MBZ, clinically useful BZs in 
canine medicine, exert direct and indirect effects against a canine osteosarcoma line in vitro. 
Direct effects of cell proliferation were apparent even at low doses (5μM) for all BZs, with the 
effect being least robust in FBZ.  One molecular mechanism of action is tubulin 
depolymerization.  All three BZs had a rapid dose independent effect, with ABZ having the 
strongest effect   Results are very similar to the effects of vinca alkaloids.  Cells arrest in G2/M 
even at very low doses (1 μM) of BZs, likely as a result of tubulin depolymerization resulting in 
MT inhibition.  Strong responses  were observed even with ABZ at 1μM, and all other drug 
concentrations demonstrated >80% cell cycle arrest.  It is likely that cell cycle arrest is one 
mechanism by which BZs induce apoptosis in the D17 cell line.  When MT polymerization is 
disrupted, the mitotic spindle does not sense tension, which is necessary for proper chromosome 
alignment and separation. This results in catastrophic failure of cellular division and cells will 
undergo apoptosis.  Apoptosis was identified at similar low concentrations, with BZ treatment 
≥1.6 μM resulting in increased apoptosis.   The apoptotic effect was least pronounced with ABZ.  
Based on PK data for ABZ and FBZ treatment doses up to 25 μM are biologically achievable 
(with oral doses of 20-125mg/kg/day, anti-parasitic doses are 25-50mg/kg/day); these doses have 
minimal adverse effects.   While PK data for MBZ is not reported in dogs, based on information 
in rodent species and the similarities in chemical characteristics to other BZs, plasma levels 
comparable to these in vitro concentrations may be achievable. While effects varied between 
drug and mechanism, overall ABZ and MBZ appear to be the most effective, and FBZ the least 
effective at equivalent micromolar concentrations.  However, pharmacologic characteristics 
including absorption and bioavailability, metabolism, and excretion may play a role in dictating 
biologic activity in vivo.   
Some BZs are also reported to have indirect anti-cancer effects via modulation of 
angiogenesis, particularly VEGF.  In our study, all BZs reduced VEGF secretion in vitro, 
although FBZ was again least effective.  As a surrogate marker for angiogenesis and a prognostic 
factor in canine OS, VEGF may also translate as a serum biomarker in pilot studies in vivo.  The 
molecular mechanism by which microtubule inhibitory drugs exert their effects on VEGF has not 
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been well described.  Microtubules regulate HIF-1via control of mRNA transport and ensuing 
HIF translation.   Taxanes and other MT disrupting agents inhibit nuclear accumulation of HIF-
1and thus HIF-1can be included with other transcription factors that utilize microtubules 
for transport during interphase.  HIF-1and/or VEGF may be regulated by MTs at both protein 
synthesis and trafficking levels. 
Known regulatory functions of HIF-1include target genes, pro-angiogenic cytokines,   
transcription factors and heat shock factor.  Various integrins and matrix metalloproteinases are 
also controlled by HIF-1 Heat shock protein 90 (HSP 90) is molecular chaperone that regulates 
the conformational stability and structure of an array of proteins.  Known HSP90 dependents 
include oncoproteins, including EGFR family members, mutant p53, Kit, Akt, Bcr-Abl and Met. 
Inhibition of HSP90 leads to degradation of the dependent proteins via the ubiquitin proteasome 
pathway ultimately resulting in apoptosis. Accumulation of over-expressed or mutated dependent 
proteins is noted in neoplasms.  HSP90 inhibitors, such as STA-1474 have recently shown 
measureable objective responses in various tumor types including dogs with osteosarcoma, mast 
cell tumors, melanoma and thyroid carcinoma. 
126
 Additional molecular effects of MTIs and the 
BZs may include alterations of HSP90 via HIF-1 The combination of BZs and HSP inhibitors 
should be investigated based on the common protein, HIF-1
Aberrant expression of tubulin is reported in multiple cancers including osteosarcoma 
and represents a more aggressive phenotype. It has also been implicated in drug resistance to 
taxols in OS cell lines.
74-76
  Based on the mechanisms of action of the MTIs, their disruption of 
polymer formation and dynamicity may be an additional avenue to address aberrations in 
tubulin expression.  Investigations of BZs on specific tubulin isotypes should be considered for 
future evaluation.   
The MTS proliferation assay showed that BZs do inhibit neoplastic OS cell proliferation. 
This was concordant with previous studies showing this effect in other tumor types following 
treatment with BZs both in vitro and in vivo. The doses at which this was achievable were those 
that are clinically achievable and well tolerated in dogs.   The effect was indeed both dose and 
time dependent as was noted in previous work.  Flow cytometry for apoptosis confirmed that the 
decrease in proliferation was indeed due to apoptosis and not necrosis.  Additionally, flow 
cytometry with DAPI showed that the vast majority of cells were arrested in the G2/M phase of 
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the cell cycle.  This supports the mechanism of microtubule inhibition as cells with defective 
MTs or who cannot form a functional mitotic spindle will ultimately arrest in G2/M.  
The tubulin polymerization assay confirmed that the mechanism of action of the BZs is 
indeed due to tubulin inhibition.  Our results showed a rapid destabilization of tubulin, similar to 
the vincristine, a known destabilize, however we observed a rapid plateau at all doses.  
Adjustments for time to collecting data points did not improve our results which are a limitation 
of both equipment capability and assay requirements. We believe that lower doses (< 1μM) 
would be needed to more specifically identify the rate of inhibition and to further classify the 
exact mechanism of the tubulin inhibition.  While the overall trend is visually similar to 
vincristine, finer data points early in the polymerization curve may hold more information.  
The treatment of OS cells with the BZs resulted in decreased serum VEGF.  Decreases in 
VEGF have been reported following treatment with other MT inhibiting drugs.  The mechanism 
of decrease is unknown and may be to be due to deregulation of HIF 1 .  HIF-1  is the direct 
upstream regulator of VEGF.  The MTs are crucial for many cellular regulatory functions 
including formation and movement of proteins, activation and movement of transcription factors 
and many, many others.  The MT inhibition caused by the BZs has the potential to affect 
multiple other factors within cellular regulation.  It is unknown if there is a single most important 
factor, such as HIF-1  or if the BZs effects on multiple levels of cellular regulation lead to an 
overall decrease in neoplastic cell survival.   
Overall, we have good evidence to suggest that the MTs do inhibit neoplastic cell growth 
via interference with MT formation, which leads to G2/M cell cycle arrest followed by apoptosis.  
More would is need to delineate the exact mechanism of the polymerization inhibition and the 
upstream effects of the BZs and how they impact VEGF secretion.  
As previously stated, our study has several limitations including the use of a single OS 
cell line to represent the heterogeneous disease of canine OS and the overall in vitro nature of the 
study which limits the immediate translational significance.  In addition, this study relies on a 
single read-out of angiogenic effect (VEGF) without knowledge of the underlying molecular 
mechanism by which it is modulated by BZs.  Soluble VEGF may not be the major anti-
angiogenic mechanism, and may not translate into a biomarker in vivo as global serum levels 
may not reflect the tumor microenvironment.  Three candidate BZs were selected based on 
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clinical use in dogs, however there are hundreds of BZ-like chemical compounds and thus ABZ 
and MBZ may not be most effective.   
Within these limitations, our data shows that BZs (ABZ, FBZ, MBZ) exert direct and 
indirect anti-cancer effects in D17 OS cells.  Specifically, tubulin depolymerization appears to 
lead to altered microtubule function and cell cycle arrest.  The cell cycle arrest demonstrated may 
result in inhibition of proliferation and induction of apoptosis seen in vitro.   Indirectly, BZs 
modulate soluble VEGF protein levels, possibly because the MT is an important functional 
element in subcellular location of HIF 1-, the upstream regulator of VEGF.  
Taken in context of the demonstrated in vitro activities and combined with the clinical 
information already available on these BZs in regards to dosage, safety, toxicity, and 
pharmacokinetics as well as the relative in expense of BZ drugs compared to traditional 
chemotherapy, BZs, particularly ABZ and MBZ, are attractive novel therapies.  They may prove 
to be beneficial as adjunctive therapy and an alternative mechanism to combat drug resistance.   
Given the heterogeneous nature of cancer and the multiple mechanisms of resistance, BZs are 
likely to be most useful when used in conjunction with traditional (maximum tolerated dose) 
chemotherapy in osteosarcoma.  In this setting, the limited toxicity is of particular benefit, as 
combination chemotherapy is often limited to additive toxicity of the drugs.  This study provides 
preliminary evidence supporting the transition of ABZ and MBZ from the bench top to live 
patients.  Further study is needed to evaluate PK and safety in cancer-bearing dogs, particularly 
if used in a combination chemotherapy setting given the potential for adverse hematologic with 
ABZ.  Cell function effects were seen even at low levels in vitro, and thus treatment to MTD 
may not be necessary to exert biologic effect in vivo.  Evaluation of serial levels of serum VEGF 
as a surrogate and transitional biomarker of biologic drug activity may aid in the estimation of 
drug effect in cancer-bearing dogs.   
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CHAPTER 6  
FIGURES AND TABLES 
 
Figure 1. The basic benzimidazole structure of a benzene and imidazole. 
 
 
 
 
  
 
 
Figure 2. Microtubule structure of-tubulin heterodimers. There are 13 protofilaments that 
form a cylinder that is 24 nm in diameter. The exposed -subunit is the plus end and the -
subunit is the minus end. Adapted from Current Cancer Drug Targets, Jordan, 2007. 
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Figure 3. Schematic representation of the curved configuration of two tubulin dimers, α1β1 and 
α2β2. Colchicine has been shown to bind between subunits of the same dimer whereas 
vinblastine binds between dimers.  Adapted from Mol. Biotechnol. Wade, 2009. 
 
 
  
 
 
 
  
 
 
 
 
 
Figure 4. Isoforms produced from alternative exon splicing of VEGF. Isoform 165 is the most 
mitogenic. Adapted from J Investig Dermatol Symp Proc. 2006, Courtesy of J. Wypij. 
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Figure 5. Transcriptional regulation of VEGF by HIF-1 complex. Atlas of Genetics and 
Cytogenetics in Oncology and Haematology (http://AtlasGeneticsOncology.org, 2008). Courtesy 
of J. Wypij. 
 
 
 
 
 
 
Figure 6. VEGF Signal Inhibition, specifically TKIs and monoclonal antibodies. From 
http://img.medscape.com/fullsize/migrated/editorial/cmelive/2007/6165/images/slide31.gif 
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Figure 7. Dose dependent inhibition of cell proliferation of D17 cell line when  
treated with albendazole at doses of 0-200μM for 24 hours. 
 
 
 
 
 
Figure 8. Dose dependent inhibition of cell proliferation of D17 cell line when  
treated with fenbendazole at doses of 0-200μM for 24 hours.  
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Figure 9. Dose dependent inhibition of cell proliferation of D17 cell  
line when treated with mebendazole at doses of 0-200μM for 24 hours. 
 
 
 
 
 
Figure 10. Comparison of albendazole, fenbendazole and mebendazole on inhibition of cell 
proliferation of D17 cell line.  
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Figure 11. Flow cytometry utilizing Annexin V-FITC. Increased numbers of apoptotic cell are 
noted at increasing concentrations (0-25μM) of mebendazole.   
  
Figure 12. Comparison of effect of albendazole, fenbendazole and mebendazole on induction of 
apoptosis in cells treated at varying concentrations for 24 hours.  
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Figure 13. Cell cycle arrest gating was based on data as shown here for ABZ at 5 μM. 
 
 
Figure 14. Flow cytometric visualization of effect of ABZ on cell cycle arrest. Cells  
treated with ABZ arrested in G2/M at doses all dose, with most pronounced effect at 
5μM-25μM.  
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Figure 15. Flow cytometric analysis of cell cycle arrest.  Cells treated with ABZ, FBZ 
and MBZ arrested in G2/M of cell cycle at doses 1μM and greater for all three drugs.  
 
 
 
 
 
Figure 16. Example of Tubulin Assay. Phases of tubulin polymerization are indicated for the 
control curve; I: nucleation, II: growth III: steady state equilibrium. 
Courtesy of Cytoskeleton, Denver CO. 
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Figure 17. Albendazole inhibits tubulin polymerization at doses from 10μM-50μM. Results are 
similar to vincristine, a tubulin destabilizer.  
 
 
 
Figure 18. Fenbendazole inhibits tubulin polymerization at doses from 10μM-50μM. Results are 
similar to vincristine, a tubulin destabilizer at lower doses, while the highest dose has minimal 
effect. 
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Figure 19. Mebendazole inhibits tubulin polymerization at doses from 10μM-50μM. Results are 
similar to vincristine, a tubulin destabilizer at all doses.  
 
 
 
 
 
Figure 20. Albendazole inhibits VEGF secretion at doses ≥1μM (p<0.01). 
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Figure 21. Fenbendazole inhibits VEGF secretion at doses ≥5μM (p<0.01).  
 
 
 
 
 
 
 
Figure 22. Mebendazole inhibits VEGF secretion at doses > 1 μM (p <0.01). 
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Figure 23. Comparison of albendazole, fenbendazole and mebendazole inhibition of VEGF 
secretion at doses from 0-200μM. 
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Table 1. Benzimidazole metabolites and their established plasma concentrations. 
References*11, **45, ***41,****126, *****127 
 
 
 Active metabolite Cmax Tmax 
ABZ Albendazole Sulfoxide 
 
 
Albendazole Oxide= 
ricobendazole 
Canine:1.81ug/ml at 
50mg/kg**** 
 
Human: 
400mg/human=0.16mg/L***** 
4.4 hrs 
 
 
4.2 hrs 
FBZ Fenbendazole Sulphone 
and Sulphoxide 
 
Oxfendazole (sulfoxide  
and sulphone forms) 
Canine: 
0-0.53ug/ml at 20mg/kg* 
 
0.42ug/ml at 20mg/kg** 
 
Unknown 
 
 
12hrs 
MBZ None known in animals 
 
Active metabolite in 
humans the 2-amine form 
Canine: Unknown 
 
Humans: 
1.5 g achieved levels >5 μg/L 
(no food) 
1.5g achieved 27-42ug/L (high 
fat meal)*** 
 
100mg BID achieved 
0.03mcg/ml MBZ and 
0.09mcg/ml of 2-Amine MBZ 
 
Rats: 40mg/kg achieved 
349 ng/ml Wistar rat*** 
Unknown 
 
Unknown 
 
 
 
 
 
Unknown 
 
 
 
Unknown 
 
OFZ Exists as a sulfoxide Canine: 2.5- 80mg/kg achieved 
0.07ug-0.14 ug/ml* 
12 hr 
48 
 
Table 2. A summary of similarities and differences between the mechanisms of antimitotic 
drugs. Adapted from Jordan, Current Cancer Drug Targets, 2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.  Effect on cell survival as assessed by flow cytometry. Results are reported as an 
average of the experiments which were performed in triplicate. 
 
 
Drug Dose μM % Survival 
ABZ Media Control (1% DMSO) 96.54 
 1 90.21 
 5 86.39 
 10 87.08 
 25 85.19 
FBZ Medial Control (1% DMSO) 95.33 
 1 88.70 
 5 89.24 
 10 87.70 
 25 59.55 
MBZ Medial Control (1% DMSO) 95.21 
 1 86.66 
 5 89.03 
 10 87.92 
 25 85.62 
 
  
 
 
 
 
 
 
 
 
Drug Mitotic Arrest at 
low and high drug 
concentrations 
MT Dynamics High Concentration 
effects on MT 
polymer mass 
Taxanes, epothilones Yes Suppressed Enhanced 
Vincas, colchicine, 
dolastains 
Yes Suppressed Depolymerized 
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Table 4.  Effect on cell cycle arrest when treated with BZ assessed by flow cytometry. Results 
are reported as an average of the experiments which were performed in triplicate. 
5μM -25μM. All results were significant at p<0.01. 
 
 
Drug Dose μM % Arrested in G2/M of cell 
cycle 
ABZ Media Control (1%DMSO) 15.79 
 1 51.88 
 5 86.81 
 10 82.17 
 25 82.53 
FBZ 1 80.8 
 5 88.4 
 10 88.2 
 25 88.0 
MBZ 1 82.23 
 5 87.82 
 10 86.07 
 25 85.35 
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